Every 10-Q that NewAmsterdam Pharma Company N.V (NAMS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NAMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAMS filings page.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company focused on CETP inhibitor obicetrapib for LDL-C lowering, reported Q2 2026 revenue of $3.7 million, down from $19.1 million as prior Menarini development contributions did not recur and revenue now reflects initial supply sales.
Research and development expenses rose to $41.7 million and selling, general and administrative expenses were $26.9 million, leading to a net loss of $64.1 million, or $0.52 per share; first-half net loss was $112.6 million. Cash, cash equivalents and marketable securities totaled $678.3 million at June 30 2026, with $69.8 million of operating cash outflows in the first half.
Operationally, the EMA’s CHMP issued a positive opinion recommending EU marketing authorization for obicetrapib monotherapy and fixed-dose combination with ezetimibe, with Menarini preparing potential launches in late 2026. The PREVAIL cardiovascular outcomes trial remains underway, with an interim analysis planned in Q4 2026 and a DSMB recommendation expected in Q1 2027.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
NewAmsterdam Pharma (NAMS) filed its Q3 2025 10‑Q, reporting revenue of $348 thousand and a net loss of $72.0 million. Operating expenses totaled $55.5 million, driven by R&D $31.0 million and SG&A $24.5 million. Other items included a $23.8 million loss from warrant fair value changes and $6.7 million of interest income.
Liquidity remains strong with $756.0 million in cash, cash equivalents and marketable securities as of September 30, 2025. During the nine months, the company recognized $16.1 million related to development cost contributions under its Menarini license and recorded initial supply revenue of $348 thousand after signing a Menarini Supply Agreement on August 12, 2025. On August 18, 2025, the EMA validated MAAs for obicetrapib 10 mg monotherapy and the obicetrapib + ezetimibe FDC. The PREVAIL outcomes trial completed enrollment in April 2024 and could conclude as early as the end of 2026 based on minimum follow‑up and event targets.